


AMENDMENT TO THE SPECIFICATION

Please replace the Abstract with the following substitute Abstract:

----- ABSTRACT


Selective MMP-13 inhibitors are fused pyrimidinones of the formula



or a pharmaceutically acceptable salt thereof,

wherein:

W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical



wherein Y , R^1 , R^4 , X , A , B , R^2 , and R^3 are as defined for Formula I in the

specification; X is O , S , SO , SO_2 , NR^5 , or CH_2 ;

\ominus $(\ominus)_n$

\parallel \parallel

A is C or S ;

B is O or NR^5 ; or

A and B are taken together to form $C \equiv C$;

R^1 , R^4 , and R^5 are hydrogen, alkyl, alkenyl, alkynyl, $(CH_2)_n$ -aryl, $(CH_2)_n$

cycloalkyl, C_1 - C_6 alkanoyl, or $(CH_2)_n$ -heteroaryl;

R^2 and R^3 are hydrogen, alkyl, alkenyl, alkynyl CN , NO_2 , NR^4R^5 , $(CH_2)_n$

cycloalkyl, $(CH_2)_n$ -aryl, or $(CH_2)_n$ -heteroaryl;

R^2 may further be halo;

n is an integer of from 0 to 5; and

R^4 and R^5 when taken together with a nitrogen to which they are both attached complete a 3 to 8 membered ring containing carbon atoms and optionally containing O , S , or N , and substituted or unsubstituted;

with the proviso that R^1 and R^3 are not both selected from hydrogen and C_1 - C_6 alkyl. -----